Trials / Completed
CompletedNCT00522145
Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib
A Phase 2 Study of XL647 in Subjects With Non-Small Cell Lung Cancer Who Have Progressed After Responding to Treatment With Either Gefitinib or Erlotinib
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Kadmon Corporation, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the best confirmed response rate of daily administration of the multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR and VEGFR2) XL647 in subjects with NSCLC who have progressed after responding to treatment with either erlotinib or gefitinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XL647 | Daily dosing as a single oral agent at a dose of 300 mg supplied as 50-mg tablets |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2009-10-01
- Completion
- 2010-02-01
- First posted
- 2007-08-29
- Last updated
- 2022-05-13
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00522145. Inclusion in this directory is not an endorsement.